Endoscopic resection techniques and ablative therapies for Barrett’s neoplasia

Table 7 Radiofrequency ablation non-randomized prospective trials

Author	n	Complete regression of intestinal metaplasia (%)	Complete regression of dysplasia/early cancer (%)	Patients	Study	Follow-up (mo)
Roorda et al[97], 2007	13	46	71	BE	Single-center	12
Sharma et al[98], 2007	70	70	-	Non D-BE	Multic.	12
Fleischer et al[99], 20081	70	70-98	-	Non D-BE	Multic.	12-30
Ganz et al[100], 2008	142	54.3	80.4-90.2	HGD	Multic.	12
Pouw et al[101], 2008	44	98	-	BE	Single-center	21
Gondrie et al[102], 2008	11	100	100	BE	Single-center	14
Gondrie et al[103], 2008	12	100	100	BE	Single-center	14
Sharma et al[104], 2008	10	90	100	LGD	Single-center	24
Hernandez et al[105], 2008	10	70	-	BE	Single-center	12
Sharma et al[106], 2009	63	79	89	LGD/HGD	Single-center	24
Velanovich[107], 2009	66	93	-	BE	Single-center	12
Vassiliou et al[108], 2010	25	78.5	-	LGD/HGD/IMC	Single-center	20
Lyday et al[109], 2010	429	72	89	LGD/HGD	Multic.	9
Eldaif et al[110], 2010	27	100	-	Non D-BE/LGD	Single-center	2
Fleischer et al[111], 20102	50	92	-	Non D-BE	Multic.	60

¹Outcomes at 2.5 years f/u;

²Outcomes at 5 years f/u. Non D-BE: Non dysplastic Barrett’s esophagus; BE: Dysplastic and non dysplastic Barrett’s esophagus; LGD: Low grade dysplasia; HGD: High grade dysplasia; IMC: Intramucosal carcinoma.